InvestorsHub Logo
Followers 2427
Posts 90866
Boards Moderated 7
Alias Born 09/12/2003

Re: TJG post# 3053

Wednesday, 02/21/2024 12:51:36 PM

Wednesday, February 21, 2024 12:51:36 PM

Post# of 6533
A Phase 3 pivotal on-target trial of Mytesi for the follow-on indication of cancer therapy-related diarrhea also known as chemotherapy-induced overactive bowel. The trial aims to address symptoms such as chronic debilitating diarrhea, GI urgency, and GI incontinence, and GI incontinence with top-line results expected before Thanksgiving.

"our Phase 3 pivotal OnTarget trial of Mytesi for the follow-on indication of the preventative treatment of cancer therapy-related diarrhea, an indication we also refer to as chemotherapy-induced overactive bowel (CIOB) - which includes symptoms such as chronic debilitating diarrhea, GI urgency, and GI incontinence. Top-line results from this pivotal study are expected before Thanksgiving."


Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent JAGX News